ARTHEX BIOTECH
Investigating antimiRs to treat diseases with unmet medical needs
Valencia · Founded 2019 · $94.4M raised
- Headquarters
- Valencia
- Founded
- 2019
- Business Model
- B2B
- Website
- arthexbiotech.com
- Total Funding
- $94.4M
- Last Round
- $4.9M Venture RoundSep 2025
- Rounds
- 3
About
ARTHEx Biotech is a clinical-stage biotechnology company spun off from the University of Valencia, focused on developing innovative medicines through modulation of microRNA expression (antimiRs). The company investigates antisense RNA compounds designed to treat diseases with unmet medical needs, including a lead program for myotonic dystrophy type 1 (DM1). Arthex is headquartered in Valencia, Spain, led by CSO and co-founder Beatriz Llamusí.
Summary
ARTHEX BIOTECH is a Biotech company based in Valencia, founded in 2019. It has raised $94.4M in total across 3 rounds, most recently a $4.9M Venture Round round in Sep 2025. Investors include European Innovation Council Fund, Invivo Capital Partners and Bpifrance.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.